Axogen Completes Acquisition of BioCircuit Technologies

Axogen, Inc. announced the completion of its acquisition of BioCircuit Technologies, Inc. on October 1, 2026. BioCircuit Technologies is a medical device company known for developing NerveTape™, the first FDA-cleared device for sutureless peripheral nerve repair. This acquisition is expected to significantly contribute to Axogen's revenue, with an estimated $6 million in the fourth quarter of 2026 and $34 million in 2027. Axogen anticipates maintaining at least 73% gross margin and achieving free cash positivity for the full year 2026. The integration of BioCircuit and its innovative NerveTape™ technology aligns with Axogen's mission to advance peripheral nerve repair solutions and establish a new standard of care in the field.